Compare GVH & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GVH | ASBP |
|---|---|---|
| Founded | 2016 | 2021 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7M | 12.4M |
| IPO Year | 2023 | 2021 |
| Metric | GVH | ASBP |
|---|---|---|
| Price | $1.01 | $8.94 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $80.00 | N/A |
| AVG Volume (30 Days) | ★ 116.1K | 24.1K |
| Earning Date | 02-17-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $102,768.97 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $0.05 |
| 52 Week High | $6.46 | $9.50 |
| Indicator | GVH | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 34.31 | 63.66 |
| Support Level | $0.87 | $4.63 |
| Resistance Level | $1.13 | N/A |
| Average True Range (ATR) | 0.05 | 0.49 |
| MACD | 0.08 | 0.04 |
| Stochastic Oscillator | 13.33 | 70.53 |
Globavend Holdings Ltd is an e-commerce logistics provider, it provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution from parcel consolidation to air freight forwarding, customs clearance, on-carriage parcel transportation and delivery. It operates in logistics and freight forwarding industry, which involves the provision of services such as freight transport, freight forwarding, warehouse management, and distribution.
Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery.